Literature DB >> 19892047

Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction.

Michał Plewka1, Maria Krzemińska-Pakuła, Piotr Lipiec, Jan Zbigniew Peruga, Tomasz Jezewski, Michał Kidawa, Karina Wierzbowska-Drabik, Anna Korycka, Tadeusz Robak, Jarosław Damian Kasprzak.   

Abstract

To investigate the effect of intracoronary injection of autologous mononuclear bone marrow stem cells (BMSCs) in patients with ST-elevation myocardial infarction (STEMI) on left ventricular (LV) systolic and diastolic function using standard echocardiography and 2-dimensional systolic strain. A total of 60 patients with first anterior wall STEMI and LV ejection fraction of <40%, treated with successful primary percutaneous coronary intervention were randomly assigned to the treatment group (BMSC group) or the control group in a 2:1 ratio. Transcatheter intracoronary injection of BMSCs into the infarct-related artery was performed 7 days after STEMI. Standard echocardiography and speckle tracking analysis was performed at baseline and 6 months after STEMI. No differences were found in the baseline echocardiographic parameters of LV systolic and diastolic dysfunction--the LV ejection fraction was 35 +/- 6% in the BMSC group, similar to that in the control group (33 +/- 7%, p = 0.42). After 6 months, the absolute change in the LV ejection fraction was significantly greater in the BMSC group than in the control group (10 +/- 9% versus 5 +/- 8%, p = 0.04). Significant improvement was seen in 2-dimensional systolic strain in all segments (12 +/- 4 vs 14 +/- 4; p = 0.0009) and in the infarcted area (5 +/- 2 vs 6 +/- 2; p = 0.0038) only in the BMSC group. Of the diastolic function parameters, we observed improvement in the early filling propagation velocity (30 +/- 8 cm/s vs 37 +/- 13 cm/s; p = 0.0008), early diastolic velocity - E' (4.5 +/- 1.5 vs 5.0 +/- 1.3, p = 0.02), and the E/E' ratio (17 +/- 7 vs 14 +/- 5; p = 0.03) in the BMSC group. In conclusion, intracoronary injection of unselected BMSCs in patients with STEMI improved both LV systolic and diastolic function at 6 months of follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19892047     DOI: 10.1016/j.amjcard.2009.06.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Current and future status of stem cell therapy in heart failure.

Authors:  David A D'Alessandro; Robert E Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-12

Review 2.  Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.

Authors:  Ronak Delewi; Alexander Hirsch; Jan G Tijssen; Volker Schächinger; Wojciech Wojakowski; Jérôme Roncalli; Svend Aakhus; Sandra Erbs; Birgit Assmus; Michal Tendera; R Goekmen Turan; Roberto Corti; Tim Henry; Patricia Lemarchand; Ketil Lunde; Feng Cao; Heikki V Huikuri; Daniel Sürder; Robert D Simari; Stefan Janssens; Kai C Wollert; Michal Plewka; Stefan Grajek; Jay H Traverse; Felix Zijlstra; Jan J Piek
Journal:  Eur Heart J       Date:  2013-09-11       Impact factor: 29.983

3.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 4.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

Review 5.  Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Authors:  Paulino A Alvarez; Ernst R Schwarz; Rajesh Ramineni; Phil Myatt; Clay Barbin; Carlos Boissonnet; Anita Phan; Aldo Maggioni; Alejandro Barbagelata
Journal:  Clin Res Cardiol       Date:  2012-09-28       Impact factor: 5.460

Review 6.  Imaging: guiding the clinical translation of cardiac stem cell therapy.

Authors:  Patricia K Nguyen; Feng Lan; Yongming Wang; Joseph C Wu
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

Review 7.  Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials.

Authors:  Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circ Res       Date:  2015-07-09       Impact factor: 17.367

8.  Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy.

Authors:  Saranya P Wyles; Satsuki Yamada; Saji Oommen; Joseph J Maleszewski; Rosanna Beraldi; Almudena Martinez-Fernandez; Andre Terzic; Timothy J Nelson
Journal:  Stem Cells Dev       Date:  2014-08-21       Impact factor: 3.272

Review 9.  Current State of Stem Cell Therapy for Ischemic Heart Disease.

Authors:  Thomas J Povsic
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

10.  Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.

Authors:  Dan Yang; Connor Galen O'Brien; Gentaro Ikeda; Jay H Traverse; Doris A Taylor; Timothy D Henry; Roberto Bolli; Phillip C Yang
Journal:  Am Heart J       Date:  2019-11-11       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.